Microba Life Sciences (ASX:MAP) Research & Development: A$1.54 Mil (TTM As of Dec. 2025)


What is Microba Life Sciences Research & Development?

Microba Life Sciences ASX:MAP Research & Development is A$1.54 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Microba Life Sciences's Research & Development for the six months ended in Dec. 2025 was A$0.28 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.54 Mil.

Microba Life Sciences  (ASX:MAP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Microba Life Sciences Research & Development Related Terms

Microba Life Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Research & Development Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Research & Development
5.38 9.34 10.84 2.01

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 7.19 3.64 0.76 1.25 0.28

Microba Life Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$1.54 Mil mean?
Microba Life Sciences (ASX:MAP) has a Research & Development of A$1.54 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Research & Development too high?
Microba Life Sciences' current Research & Development is A$1.54 Mil.
How does Microba Life Sciences' Research & Development compare to TMO and DHR?
Microba Life Sciences' Research & Development of A$1.54 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Research & Development is A$1.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current Research & Development is A$1.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Research & Development is A$1.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.